Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||18 Years and Over|
Inclusion Criteria:Cohort 1 (Advanced): Measurable stage IIIB, IIIC, IIID or IV melanoma with clinical or radiological evidence of disease. These participants may have had cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma. Staging must be confirmed by cytological or histological examination. Staging of cutaneous melanoma will be based on the revised AJCC 8th Edition staging system (Appendix 2) 66. Cohort 2 (Neo-adjuvant): Resectable stage IIIB, IIIC, IIID, or IV melanoma at initial presentation or subsequent recurrence. These participants have disease amenable to complete surgical resection at the time of enrollment in the study. The resectable disease does not need to be measurable by RECIST v1.1 criteria. Cohort 3 (Adjuvant): Participants with stage IIIA, IIIB, IIIC, IIID or IV melanoma resected to no evidence of disease. Participants must initiate therapy within 12 weeks of last surgical resection and within 12 weeks of being rendered clinically free of disease by non-surgical approaches Patients that have undergone ablative therapy to a metastatic lesion (e.g. GKRS, radiofrequency ablation) that manifest no additional sites of disease at enrollment are eligible for treatment on cohort 3.
- - Participants must be eligible to be treated with BRAF inhibitor and MEK inhibitor combination.
- - Participants with prior therapy with targeted therapies specific for mutated BRAF including BRAF and/or MEK inhibitors are eligible provided that there was clinical benefit to prior therapy with these agents as judged by the treating physician.
- - Participants will be required to have radiological studies at baseline to establish measurable disease for cohort 1 or to prove lack of distant metastases for cohorts 2 and 3.
- - Chest CT scan, - Abdominal and pelvic CT scan, and.
- - Head CT scan or MRI.
- - Participants in cohorst 1 & 2 who have metastatic melanoma safely available for biopsy pretreatment and on day 22 must consent to having those biopsies.
- - 3.1.
- - Each brain metastasis must have been completely removed by surgery or each unresected brain metastasis must have been treated with stereotactic radiosurgery or systemic immunotherapy.
- - There has been no evident growth of any brain metastasis since the most recent treatment if the last treatment is >4 weeks prior to enrollment.
- - No brain metastasis is > 2 cm in diameter at the time of registration.
- - Neurologic symptoms have returned to baseline off steroids, - Subjects are not using steroids for at least 7 days prior to registration.
- - The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed ≥ 1 week prior to registration.
- - ECOG performance status of 0-2.
- - Participants must have the ability and willingness to give informed consent.
- - Laboratory parameters as follows: - ANC > 1000/mm3.
- - Platelets > 100,000/mm3.
- - Hgb > 9 g/dL.
- - HgB-A1c ≤ 8.5% - AST and ALT up to 2.5 x upper limits of normal (ULN).
- - Bilirubin up to 2.5 x ULN.
- - Alkaline phosphatase up to 2.5 x ULN.
- - Creatinine up to 1.5 x ULN.
- - Age 18 years or older at registration.
- - Participants must have at least two intact (undissected) axillary and/or inguinal lymph node basins.
- - Participants who have received the following medications or treatments at any time within 4 weeks of registration: - • Chemotherapy.
- - Interferon (e.g. Intron-A®) - Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥ 1 week and ≤ 6 months prior to registration) - Allergy desensitization injections.
- - Corticosteroids, administered transdermally, parenterally or orally.
- - Growth factors (e.g. Procrit®, Aranesp®, Neulasta®) - Interleukins (e.g. Proleukin®) - Any investigational medication.
- - HIV positivity or evidence of active Hepatitis C virus.
- - Participants who are currently receiving nitrosoureas or who have received this therapy 6 weeks prior to registration.
- - Participants who are currently receiving a checkpoint molecule blockade therapy, or who have received this therapy within 3weeks prior to registration.
- - Participants with known or suspected allergies to any component of the vaccine.
- - Participants may not have been vaccinated previously with any of the synthetic peptides included in this protocol.
- - Pregnancy.
- - Female participants must not be breastfeeding.
- - Participants in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol in the opinion of the investigator.
- - Participants classified according to the New York Heart Association classification as having Class III or IV heart disease.
- - Participants with uncontrolled diabetes, defined as having a HgB-A1c greater than 7.5%.
- - Participants must not have had prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement.
- - Participants who have another cancer diagnosis, except that the following diagnoses will be allowed: - squamous cell cancer of the skin without known metastasis.
- - basal cell cancer of the skin without known metastasis.
- - carcinoma in situ of the breast (DCIS or LCIS) - carcinoma in situ of the cervix.
- - any cancer without distant metastasis that has been treated successfully, without evidence of recurrence or metastasis for over 3 years.
- - Participants with known addiction to alcohol or drugs who are actively taking those agents, or participants with recent (within 1 year of registration) or ongoing illicit IV drug use.
- - Body weight < 110 pounds.
- - Participants with a known history of glucose-6-phosphate dehydrogenase deficiency.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
|Early Phase 1|
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|Craig L Slingluff, Jr|
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Elizabeth Gaughan, MDCraig L. Slingluff, Jr., MD|
|Principal Investigator Affiliation||University of VirginiaUniversity of Virginia|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
Experimental: 6MHP and dabrafenib and trametinib
The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously. Dabrafenib is a small molecular BRAF inhibitor and will be administered in accordance with the prescribing information: 150 mg orally twice daily taken at least 1 hour before or at least 2 hours after a meal; the doses will be approximately 12 hours apart. Trametinib is a small molecular MEK1 and MEK2 inhibitor and will be administered in accordance with the prescribing information: 2 mg orally once daily taken at least 1 hour before or at least 2 hours after a meal. The medication will be taken at the same time each day with either the morning or evening dose of dabrafenib.
Drug: - dabrafenib
Biological: - 6MHP
6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Drug: - Trametinib
MEK1 AND MEK2 inhibitor
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.